JDD July Issue Highlights | Skin of Color Issue
skin of colorThe July issue of the Journal of Drugs in Dermatology (JDD) focuses on skin of color topics with the perfect mix of original articles, case reports, brief communications, and letters to the editor. Among many of the topics explored in this issue are skin of color dermatology on TikTok, disparities in melanoma recognition in skin of color, diversity in acne clinical trials, dermatologists at skin o …
skin of color
Pop Quiz #174
The correct answer is A. MEK inhibitor. Plexiform neurofibromas occur in neurofibromatosis. Selumetinib is a mitogen-activated protein kinase (MEK) inhibitor approved for use in patients age 2 years or older, for inoperable symptomatic plexiform neurofibromas. mTOR inhibitors, such as Sirolimus, are used in the topical treatment of angiofibromas with tuberous sclerosis. BRAF inhibitors, …
JDD Issue Highlights | June 2022: Acne & Rosacea
acneThe June 2022 issue of the Journal of Drugs in Dermatology (JDD) focuses on acne and rosacea, with original articles discussing topics such as improving rosacea outcomes in skin of color patients, pediatric and female acne, topical management of facial and truncal acne, and many more. Included in this issue are also case reports on bullous dermatitis and low dose Naltrexone in combination with PRP …
acne
Pop Quiz #171
The correct answer is D. 50-75%. Explanation: The image shows neonatal lupus (see image Figure 3.1.1 in DIR). This condition presents in infants born to mothers with SLE, RA, Sjogren syndrome, or other connective tissue disorders. Dermatologic findings are seen in 50-75% of cases with pink plaques on photosensitive areas, and classic “raccoon eyes” periorbitally. The other answers ar …
Choosing Your Career Path After Dermatology Residency: Are You Ready?
dermatology residencyAt the 2022 ODAC Dermatology, Aesthetic & Surgical Conference, a resident directed series included a panel on choosing your next steps after dermatology residency – Fellowship, Academics, or Private Practice, It’s Decision Time. The panel had an impressive group of dermatologists who answered a series of questions about paving our future paths in dermatology. Here are our panel members, in …
dermatology residency
error

Enjoy this blog? Please spread the word :)